Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer

Area of Science:

• Gynecologic Oncology
• Genomic Medicine
• Translational Oncology

Background:

• Endometrial cancer (EC) is a prevalent gynecologic malignancy with rising incidence and mortality.
• Systemic treatment options for advanced or recurrent EC have been historically limited.
• The Cancer Genome Atlas (TCGA) identified four distinct EC molecular subgroups, revolutionizing understanding.

Purpose of the Study:

• To review the current therapeutic landscape for advanced and recurrent endometrial cancer.
• To highlight recent advancements in treatment options driven by molecular insights.
• To discuss the impact of precision oncology on EC management.

Main Methods:

• Review of current literature on endometrial cancer therapeutics.
• Analysis of recent clinical trials and genomic studies.
• Consultation of NCCN Guidelines for Uterine Neoplasms.

Main Results:

• Genomic characterization has led to a better understanding of EC heterogeneity.
• Precision oncology approaches are expanding treatment options for advanced/recurrent EC.
• Therapeutic landscape has evolved significantly, offering new hope.

Conclusions:

• Recent advancements in understanding EC molecular drivers have improved treatment strategies.
• Precision medicine is crucial for managing advanced and recurrent endometrial cancer.
• Continued research and adherence to guidelines are vital for optimal patient outcomes.